Economic and Clinical Burden of Diagnosed Congenital Cytomegalovirus Disease in France During the First 2 Years of Life
Author(s)
Philip Buck, PhD1, Maryaline Catillon, PhD2, Kathleen Chen, HBSc3, Kirsten Gallant, MSc4, Victor Lhoste, PhD5, Noam Kirson, PhD6, Urvi Desai, PhD6, John Diaz-Decaro, PhD1.
1Moderna, Inc., Cambridge, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Analysis Group, Inc., Montréal, QC, Canada, 4Analysis Group, Ltd., London, United Kingdom, 5Analysis Group, Ltd., Paris, France, 6Analysis Group, Inc., Boston, MA, USA.
1Moderna, Inc., Cambridge, MA, USA, 2Analysis Group, Inc., New York, NY, USA, 3Analysis Group, Inc., Montréal, QC, Canada, 4Analysis Group, Ltd., London, United Kingdom, 5Analysis Group, Ltd., Paris, France, 6Analysis Group, Inc., Boston, MA, USA.
OBJECTIVES: Congenital cytomegalovirus (cCMV) is the leading infectious cause of birth defects. This study assessed healthcare resource utilization (HRU), direct costs, and cCMV-related clinical outcomes among infants diagnosed with cCMV in France.
METHODS: This retrospective study used the Système National des Données de Santé database (01/01/2015-31/12/2023) to select cases with a first diagnosis (index date) of cCMV (ICD-10: P35.1) or CMV (ICD-10: B25.x) within 1 month of birth. cCMV cases were matched 1:1 to non-cCMV controls (index date randomly selected from all claims within 1 month of birth) on birth year, sex, region of residence, and index year. Patients were required to have ≥ 2 years of follow-up after the index date. HRU, costs (2023 euro [€]), and clinical outcomes were summarized over the 2 years post-diagnosis (observation period).
RESULTS: Of the 1,434 matched pairs, cases had longer birth admission length of stay (mean: 24.6 vs. 6.4 days) and higher birth admission costs (mean [median]: €18,759 [€3,804] vs. €3,529 [€1,136]) than controls (both p<0.001). During the observation period, the mean number of medical visits was higher among cCMV cases than controls (Year 1: 33.7 vs. 18.9; Year 2: 22.6 vs. 12.5), and more cCMV cases than controls had ≥ 1 inpatient admission (Year 1: 47.4% vs. 20.3%; Year 2: 25.9% vs. 14.6%) (all p<0.001). Cases also had higher medical costs than controls in post-index Year 1 (mean [median]: €3,726 [€1,301] vs. €1,870 [€473]) and Year 2 (€1,759 [€453] vs. €1,019 [€254]) (both p<0.001). Relatedly, during the observation period, cases experienced more clinical events potentially related to cCMV than controls (45.7 % vs. 8.4 %), with liver-related conditions being the most commonly diagnosed (29.2% vs. 5.5%) (both p<0.001).
CONCLUSIONS: In France, infants with diagnosed cCMV have higher HRU and costs, and experienced worse clinical outcomes during the first 2 years post-diagnosis compared with non-CMV controls.
METHODS: This retrospective study used the Système National des Données de Santé database (01/01/2015-31/12/2023) to select cases with a first diagnosis (index date) of cCMV (ICD-10: P35.1) or CMV (ICD-10: B25.x) within 1 month of birth. cCMV cases were matched 1:1 to non-cCMV controls (index date randomly selected from all claims within 1 month of birth) on birth year, sex, region of residence, and index year. Patients were required to have ≥ 2 years of follow-up after the index date. HRU, costs (2023 euro [€]), and clinical outcomes were summarized over the 2 years post-diagnosis (observation period).
RESULTS: Of the 1,434 matched pairs, cases had longer birth admission length of stay (mean: 24.6 vs. 6.4 days) and higher birth admission costs (mean [median]: €18,759 [€3,804] vs. €3,529 [€1,136]) than controls (both p<0.001). During the observation period, the mean number of medical visits was higher among cCMV cases than controls (Year 1: 33.7 vs. 18.9; Year 2: 22.6 vs. 12.5), and more cCMV cases than controls had ≥ 1 inpatient admission (Year 1: 47.4% vs. 20.3%; Year 2: 25.9% vs. 14.6%) (all p<0.001). Cases also had higher medical costs than controls in post-index Year 1 (mean [median]: €3,726 [€1,301] vs. €1,870 [€473]) and Year 2 (€1,759 [€453] vs. €1,019 [€254]) (both p<0.001). Relatedly, during the observation period, cases experienced more clinical events potentially related to cCMV than controls (45.7 % vs. 8.4 %), with liver-related conditions being the most commonly diagnosed (29.2% vs. 5.5%) (both p<0.001).
CONCLUSIONS: In France, infants with diagnosed cCMV have higher HRU and costs, and experienced worse clinical outcomes during the first 2 years post-diagnosis compared with non-CMV controls.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO81
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Clinical Outcomes Assessment
Disease
Infectious Disease (non-vaccine), Pediatrics